GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Short Percentage of Float

IPHYF (Innate Pharma) Short Percentage of Float


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Innate Pharma's Short Percentage of Float

For the Biotechnology subindustry, Innate Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Short Percentage of Float falls into.


;
;

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ALCLS XPAR:NANO XPAR:IVA XPAR:GNFT XPAR:OSE XPAR:ALSEN XPAR:DBV XPAR:TNG XPAR:MAAT XPAR:ADOC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IPHA:USA 0EVI:UK IPH:France IDDA:Germany IDDA:Germany IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.